[{"id":"f2099dc8-cbfe-4cc7-a261-30a50590ba1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06547112","created_at":"2025-02-25T12:39:11.165Z","updated_at":"2025-02-25T12:39:11.165Z","phase":"Phase 1","brief_title":"A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization","source_id_and_acronym":"NCT06547112","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aphexda (motixafortide)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-24"},{"id":"bc60677c-4765-447b-a7fc-484791749d8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02907099","created_at":"2021-01-18T14:15:50.444Z","updated_at":"2025-02-25T14:01:05.330Z","phase":"Phase 2","brief_title":"Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02907099","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Aphexda (motixafortide)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 10/06/2023","primary_completion_date":" 10/06/2023","study_txt":" Completion: 10/06/2023","study_completion_date":" 10/06/2023","last_update_posted":"2025-02-19"},{"id":"f3c62253-8046-49b1-bb25-cd529c350b91","acronym":"MORPHEUS-PDAC","url":"https://clinicaltrials.gov/study/NCT03193190","created_at":"2021-01-18T15:44:27.682Z","updated_at":"2025-02-25T16:36:54.744Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","source_id_and_acronym":"NCT03193190 - MORPHEUS-PDAC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • Cotellic (cobimetinib) • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Actemra IV (tocilizumab) • tiragolumab (RG6058) • etrumadenant (AB928) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide) • selicrelumab (RG7876) • simlukafusp alfa (RG7461)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 07/05/2017","start_date":" 07/05/2017","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2025-02-06"},{"id":"62911df7-cdd6-497a-b828-0b10ea364db9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06514508","created_at":"2025-02-27T07:51:39.520Z","updated_at":"2025-02-27T07:51:39.520Z","phase":"Phase 3","brief_title":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","source_id_and_acronym":"NCT06514508","lead_sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aphexda (motixafortide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-07-23"},{"id":"5339312c-848e-4c0d-aed2-e48d851689d4","acronym":"MORPHEUS-EC","url":"https://clinicaltrials.gov/study/NCT03281369","created_at":"2021-01-18T16:12:10.112Z","updated_at":"2024-07-02T16:35:06.566Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","source_id_and_acronym":"NCT03281369 - MORPHEUS-EC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • TIGIT","pipe":" | ","alterations":" HER-2 negative • HER-2 expression","tags":["HER-2 • PD-L1 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 410","initiation":"Initiation: 10/13/2017","start_date":" 10/13/2017","primary_txt":" Primary completion: 08/24/2024","primary_completion_date":" 08/24/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-05-01"},{"id":"b2e75f74-db69-4c42-84da-91c55330e291","acronym":"GENESIS","url":"https://clinicaltrials.gov/study/NCT03246529","created_at":"2021-01-18T16:02:27.221Z","updated_at":"2024-07-02T16:35:20.176Z","phase":"Phase 3","brief_title":"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous TransplantatIon in Subjects With MM","source_id_and_acronym":"NCT03246529 - GENESIS","lead_sponsor":"BioLineRx, Ltd.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aphexda (motixafortide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 12/22/2020","primary_completion_date":" 12/22/2020","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2024-02-08"},{"id":"dfd7ee50-87ba-4fb1-b93e-f7b46ce89192","acronym":"","url":"https://clinicaltrials.gov/study/NCT02639559","created_at":"2021-01-18T12:50:23.655Z","updated_at":"2024-07-02T16:35:30.301Z","phase":"Phase 2","brief_title":"Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies","source_id_and_acronym":"NCT02639559","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aphexda (motixafortide)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 03/31/2016","start_date":" 03/31/2016","primary_txt":" Primary completion: 04/12/2018","primary_completion_date":" 04/12/2018","study_txt":" Completion: 04/07/2023","study_completion_date":" 04/07/2023","last_update_posted":"2023-11-06"},{"id":"b5445d2d-9729-4b0e-9b25-92f0c973a551","acronym":"","url":"https://clinicaltrials.gov/study/NCT02115672","created_at":"2021-01-18T09:47:26.937Z","updated_at":"2024-07-02T16:37:29.784Z","phase":"Phase 1/2","brief_title":"Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT02115672","lead_sponsor":"Sheba Medical Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Aphexda (motixafortide)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 11/01/2016","primary_completion_date":" 11/01/2016","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2016-08-15"}]